Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Defining drug-free remission of skin disease in patients with plaque psoriasis.

Armstrong AW, Blauvelt A, Crowley JJ, Gordon KB, Krueger GG, Krueger JG, Sobell JM, Strober BE, Srivastava B, Menter A.

Br J Dermatol. 2019 Nov 9. doi: 10.1111/bjd.18694. [Epub ahead of print]

PMID:
31705649
2.

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.

Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2020 Jan;82(1):161-201. doi: 10.1016/j.jaad.2019.08.049. Epub 2019 Nov 5.

PMID:
31703821
3.

Part I. Hidradenitis Suppurativa: Epidemiology, clinical presentation, and pathogenesis.

Goldburg SR, Strober BE, Payette MJ.

J Am Acad Dermatol. 2019 Oct 8. pii: S0190-9622(19)32827-0. doi: 10.1016/j.jaad.2019.08.090. [Epub ahead of print] Review.

PMID:
31604104
4.

Part 2. Current and emerging treatments for hidradenitis suppurativa.

Goldburg SR, Strober BE, Payette MJ.

J Am Acad Dermatol. 2019 Oct 8. pii: S0190-9622(19)32826-9. doi: 10.1016/j.jaad.2019.08.089. [Epub ahead of print] Review.

PMID:
31604100
5.

Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry.

Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE.

J Dermatolog Treat. 2019 Oct 3:1-8. doi: 10.1080/09546634.2019.1656797. [Epub ahead of print]

PMID:
31581919
6.

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.

Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Sep;81(3):775-804. doi: 10.1016/j.jaad.2019.04.042. Epub 2019 Jul 25. Erratum in: J Am Acad Dermatol. 2019 Nov 16;:.

PMID:
31351884
7.

US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry.

Strober BE, Germino R, Guana A, Greenberg JD, Litman HJ, Guo N, Lebwohl M.

J Dermatolog Treat. 2019 Apr 29:1-9. doi: 10.1080/09546634.2019.1603361. [Epub ahead of print]

PMID:
31035822
8.

Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.

Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, Ramachandran P, Ott E, Strober BE.

Drug Saf. 2019 Jun;42(6):809. doi: 10.1007/s40264-019-00816-3.

9.

Laboratory Monitoring Requirements During Mycophenolate Mofetil Therapy for Dermatologic Conditions: A Single Institution Retrospective Chart Review.

Waldman R, Strober BE.

J Am Acad Dermatol. 2019 Feb 21. pii: S0190-9622(19)30331-7. doi: 10.1016/j.jaad.2019.02.040. [Epub ahead of print] No abstract available.

PMID:
30797844
10.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13. Review.

PMID:
30772098
11.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13. Review.

PMID:
30772097
12.

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.

Ghosh S, Gensler LS, Yang Z, Gasink C, Chakravarty SD, Farahi K, Ramachandran P, Ott E, Strober BE.

Drug Saf. 2019 Jun;42(6):751-768. doi: 10.1007/s40264-019-00797-3. Erratum in: Drug Saf. 2019 Apr 22;:.

13.

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry.

Mease PJ, Palmer JB, Hur P, Strober BE, Lebwohl M, Karki C, Reed GW, Etzel CJ, Greenberg JD, Helliwell PS.

J Eur Acad Dermatol Venereol. 2019 May;33(5):886-892. doi: 10.1111/jdv.15443. Epub 2019 Mar 5.

14.

Clinical Goals and Barriers to Effective Psoriasis Care.

Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, Cohen AD, de la Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB.

Dermatol Ther (Heidelb). 2019 Mar;9(1):5-18. doi: 10.1007/s13555-018-0279-5. Epub 2018 Dec 21.

15.

Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Tha├ži D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R.

Br J Dermatol. 2019 Jan;180(1):67-75. doi: 10.1111/bjd.17149. Epub 2018 Oct 10.

PMID:
30188571
16.

Core Outcome Sets for Psoriasis Clinical Trials: Definition, Consensus, and Acceptance.

Strober BE, Gordon KB.

JAMA Dermatol. 2018 Oct 1;154(10):1135. doi: 10.1001/jamadermatol.2018.1166. No abstract available.

PMID:
29874363
17.

Dupilumab in the Treatment of Dyshidrosis: A Report of Two Cases.

Weston GK, Hooper J, Strober BE.

J Drugs Dermatol. 2018 Mar 1;17(3):355-356.

PMID:
29537454
18.

Methotrexate treatment of generalized granuloma annulare: a retrospective case series.

Naka F, Strober BE.

J Dermatolog Treat. 2018 Nov;29(7):720-724. doi: 10.1080/09546634.2018.1447075. Epub 2018 Mar 14.

PMID:
29488435
19.

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.

Strober BE, Langley RGB, Menter A, Magid M, Porter B, Fox T, Safi J Jr, Papavassilis C.

Br J Dermatol. 2018 Feb;178(2):e105-e107. doi: 10.1111/bjd.16051. Epub 2017 Dec 22. No abstract available.

PMID:
28991372
20.

How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials.

Wan MT, Strober BE, Wu JJ, Shin DB, Gelfand JM.

J Am Acad Dermatol. 2017 Sep;77(3):569-572. doi: 10.1016/j.jaad.2017.05.032. Review. No abstract available.

21.

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.

Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE.

J Dermatolog Treat. 2017 Sep;28(6):492-499. doi: 10.1080/09546634.2017.1294727. Epub 2017 Mar 7. Erratum in: J Dermatolog Treat. 2017 Sep;28(6):571.

PMID:
28266243
22.

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.

Martin G, Strober BE, Leonardi CL, Gelfand JM, Blauvelt A, Kavanaugh A, Stein Gold L, Berman B, Rosen T, Stockfleth E.

J Clin Aesthet Dermatol. 2016 Sep;9(9 Suppl 1):S5-S29. Epub 2016 Sep 1. No abstract available.

23.

Why Biologic Therapies Sometimes Lose Efficacy.

Strober BE.

Semin Cutan Med Surg. 2016 Jun;35(4 Suppl 4):S78-80. doi: 10.12788/j.sder.2016.022.

PMID:
27525443
24.

Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.

Wu JJ, Strober BE, Hansen PR, Ahlehoff O, Egeberg A, Qureshi AA, Robertson D, Valdez H, Tan H, Wolk R.

J Am Acad Dermatol. 2016 Nov;75(5):897-905. doi: 10.1016/j.jaad.2016.06.012. Epub 2016 Aug 4.

PMID:
27498960
25.

New Therapies for Psoriasis.

Strober BE.

Semin Cutan Med Surg. 2016 Jun;35(4S):S71-S73. doi: 10.12788/j.sder.2016.020.

PMID:
29850660
26.

Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series.

Klufas DM, Wald JM, Strober BE.

Pediatr Dermatol. 2016 Mar-Apr;33(2):142-9. doi: 10.1111/pde.12782. Epub 2016 Feb 12.

PMID:
26871417
27.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).

Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, Goyal K, Fakharzadeh S, Calabro S, Langholff W, You Y, Galindo C, Lee S, Lebwohl MG.

J Am Acad Dermatol. 2016 May;74(5):851-61.e4. doi: 10.1016/j.jaad.2015.12.017. Epub 2016 Feb 4.

28.
29.

Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exercise.

Strober BE, Griffiths CE, O'Dell SJ, Tebbey PW, Barker JN; International Psoriasis Council.

Br J Dermatol. 2016 Jan;174(1):212-5. doi: 10.1111/bjd.13980. Epub 2015 Nov 8. No abstract available.

PMID:
26114971
30.

Interferon beta-1a-induced morphea.

Bezalel SA, Strober BE, Ferenczi K.

JAAD Case Rep. 2014 Oct 5;1(1):15-7. doi: 10.1016/j.jdcr.2014.10.002. eCollection 2015 Jan. No abstract available.

31.

Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report.

Babalola O, Lakdawala N, Strober BE.

JAAD Case Rep. 2014 Sep 19;1(1):3-4. doi: 10.1016/j.jdcr.2014.09.002. eCollection 2015 Jan. No abstract available.

32.

Current and future oral systemic therapies for psoriasis.

Kelly JB 3rd, Foley P, Strober BE.

Dermatol Clin. 2015 Jan;33(1):91-109. doi: 10.1016/j.det.2014.09.008. Review.

PMID:
25412786
33.

The use of self-administered subcutaneous methotrexate for the treatment of psoriasis.

Chiaravalloti AJ, Strober BE.

J Drugs Dermatol. 2014 Aug;13(8):929-31.

PMID:
25116970
34.

Similar names for similar biologics.

Casadevall N, Felix T, Strober BE, Warnock DG.

BioDrugs. 2014 Oct;28(5):439-44. doi: 10.1007/s40259-014-0099-9.

PMID:
25001080
35.

Tumor necrosis factor inhibitors in psoriasis: an update.

Kerdel FA, Strober BE.

Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S31-6. doi: 10.12788/j.sder.0066.

PMID:
24979543
36.

Methotrexate and cyclosporine in psoriasis revisited.

Strober BE.

Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S27-30. doi: 10.12788/j.sder.0066.

PMID:
24979542
37.

Understanding therapeutic pathways and comorbidities in psoriasis.

Gordon KB, Strober BE.

Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S20-3. doi: 10.12788/j.sder.0067.

PMID:
24979540
38.

Practice gaps. Methotrexate-induced liver toxicity: replacing the liver biopsy.

Strober BE.

JAMA Dermatol. 2014 Aug;150(8):862-3. doi: 10.1001/jamadermatol.2014.681. No abstract available.

PMID:
24965863
39.

Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy.

Strober BE, Poulin Y, Teller C, Wang Y, Williams DA, Goldblum OM.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1701-6. doi: 10.1111/jdv.12372. Epub 2014 Jan 15.

PMID:
24422992
40.

Item-level psychometric properties for a new patient-reported psoriasis symptom diary.

Strober BE, Nyirady J, Mallya UG, Guettner A, Papavassilis C, Gottlieb AB, Elewski BE, Turner-Bowker DM, Shields AL, Gwaltney CJ, Lebwohl M.

Value Health. 2013 Sep-Oct;16(6):1014-22. doi: 10.1016/j.jval.2013.07.002.

41.

Treatment of atopic dermatitis in pregnancy.

Babalola O, Strober BE.

Dermatol Ther. 2013 Jul-Aug;26(4):293-301. doi: 10.1111/dth.12074. Review.

PMID:
23914886
42.

Management of psoriasis in pregnancy.

Babalola O, Strober BE.

Dermatol Ther. 2013 Jul-Aug;26(4):285-92. doi: 10.1111/dth.12073. Review.

PMID:
23914885
43.

The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument.

Lebwohl M, Swensen AR, Nyirady J, Kim E, Gwaltney CJ, Strober BE.

Int J Dermatol. 2014 Jun;53(6):714-22. doi: 10.1111/j.1365-4632.2012.05798.x. Epub 2013 Apr 4.

PMID:
23557000
44.

Pharmacovigilance and biosimilars: considerations, needs and challenges.

Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG.

Expert Opin Biol Ther. 2013 Jul;13(7):1039-47. doi: 10.1517/14712598.2013.783560. Epub 2013 Mar 26. Review.

PMID:
23527621
45.

Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.

de Souza A, Ali-Shaw T, Reddy SM, Fiorentino D, Strober BE.

Br J Dermatol. 2013 Jan;168(1):210-2. doi: 10.1111/j.1365-2133.2012.11206.x.

PMID:
23278559
46.

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.

Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M.

Dermatol Ther (Heidelb). 2012 Dec;2(1):2. doi: 10.1007/s13555-012-0002-x. Epub 2012 Mar 30.

47.

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1.

Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M.

Dermatol Ther (Heidelb). 2012 Dec;2(1):1. doi: 10.1007/s13555-012-0001-y. Epub 2012 Mar 17.

48.

Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.

De Souza A, Strober BE, Merola JF, Oliver S, Franks AG Jr.

J Drugs Dermatol. 2012 Oct;11(10):1224-6.

PMID:
23134988
49.

Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.

Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH.

JAMA Dermatol. 2013 Jan;149(1):25-32. doi: 10.1001/2013.jamadermatol.541.

50.

Ethical considerations when prescribing biologics in dermatology.

Santoro FA, Rothe MJ, Strober BE.

Clin Dermatol. 2012 Sep-Oct;30(5):492-5. doi: 10.1016/j.clindermatol.2011.06.018.

PMID:
22902219

Supplemental Content

Loading ...
Support Center